腹主动脉血管腔内修复术后患者分次团注与单次团注静脉对比剂注射方案的比较
本研究比较腹主动脉血管腔内修复(EVAR)术后患者分次团注CTA(SB-CTA)与单次团注CTA(SI-CTA)的可行性与准确性,纳入56例患者共112次检查。结果显示两种方案主动脉衰减与CNR无差异,SB-CTA改善了静脉结构和实质器官的强化及主观图像质量,18/56(32.1%)内漏均未漏诊,SB-CTA检出更多偶然发现。
要点
- SB-CTA与SI-CTA主动脉衰减和CNR无差异,静脉及实质器官强化SB-CTA更优。
- SB-CTA未漏诊任何内漏,18/56(32.1%)内漏全部可见。
- SB-CTA检出偶然发现更多(158/56 vs 135/56),并可更好表征需进一步评估的发现。
核心结论
- EVAR术后随访中分次团注CTA可可靠显示内漏,并改善主观和客观图像质量。
研究设计与样本
- 经IRB批准的研究,纳入EVAR术后接受SB-CTA和SI-CTA的患者56例(112次影像检查,平均年龄75±9岁),评估血管和实质器官的衰减与CNR,并由两名独立阅片者评估主观强化、3D重建质量和实质器官强化期相。
关键影像表现/征象
- SB-CTA与SI-CTA主动脉衰减无差异(310±87 vs 311±80 HU,p=0.88),CNR无差异(31.1±12.6 vs 29.0±12.2,p=0.20)。SB-CTA静脉结构和实质器官强化更优:门静脉149±33 vs 88±32 HU、CNR 11.6±5.6 vs 4.3±3.4;肝脏91±19 vs 68±20 HU、CNR 4.4±2.8 vs 2.1±2.0;胰腺108±27 vs 82±23 HU、CNR 6.4±3.1 vs 3.6±2.4(p<0.0001)。主观评估静脉、肝、脾、肠和肾强化改善(p<0.001),主动脉(p=0.46)和3D重建(p=0.58)无差异。
诊断标准与关键数值
- SB-CTA未漏诊任何内漏(18/56,32.1%)。SB-CTA检出偶然发现158/56,SI-CTA检出135/56(p<0.001)。SB-CTA能充分表征SI-CTA中需进一步评估的发现中的7/15(47%);SI-CTA漏诊而SB-CTA检出的偶然发现中有4/15(26%)需进一步评估。
临床应用与阅片要点
- EVAR术后随访CTA可采用分次团注方案,在保持主动脉和内漏评估能力的同时改善静脉和实质器官强化,并检出更多偶然发现。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To investigate the feasibility and accuracy of a split-bolus contrast injection CTA (SB-CTA) compared to a single-bolus injection CTA (SI-CTA) protocol of post-EVAR patients.
MATERIALS AND METHODS: In this IRB-approved study, patients who underwent SB-CTA and SI-CTA after EVAR were evaluated. Attenuation and contrast-to-noise ratio (CNR) of vessels and parenchymal organs were assessed. Subjective enhancement of vessels, quality of 3D reconstructions, and enhancement phase of parenchymal organs were assessed by two independent readers. Endoleak visibility and incidental findings were evaluated.
RESULTS: Fifty-six patients with SB-CTA and SI-CTA at two different time points after EVAR were included in the study (112 imaging studies, mean age 75 ± 9 years). There was no difference in attenuation and CNR for aorta between SB-CTA and SI-CTA (310 ± 87 vs. 311 ± 80 HU, p = 0.88; 31.1 ± 12.6 vs. 29.0 ± 12.2, p = 0.20), although both were improved in the venous structures and parenchymal organs with SB-CTA (portal vein: 149 ± 33 vs. 88 ± 32 HU, 11.6 ± 5.6 vs. 4.3 ± 3.4; liver: 91 ± 19 vs. 68 ± 20 HU, 4.4 ± 2.8 vs. 2.1 ± 2.0; pancreas: 108 ± 27 vs. 82 ± 23 HU, 6.4 ± 3.1 vs. 3.6 ± 2.4; p < 0.0001). Subjectively, enhancement of veins, liver, spleen, bowel, and kidneys was improved (p < 0.001), while there was no difference for the aorta (p = 0.46) and 3D reconstructions (p = 0.58). None of the 18/56 (32.1%) endoleaks was missed with the SB-CTA. More incidental findings were detected with SB-CTA (158/56) compared to SI-CTA (135/56), p < 0.001. SB-CTA was able to adequately characterize 7/15 (47%) of the findings that needed further evaluation in SI-CTA. 4/15 (26%) incidental findings that were missed with SI-CTA but seen with SB-CTA required further evaluation.
CONCLUSION: Split-bolus injection CTA in the follow-up of EVAR patients allows reliable visualization of endoleaks with improved subjective and objective image quality.
引用
- Boos J, Raptopoulos V, Brook A, et al. Split-bolus intravenous contrast material injection vs. single-bolus injection in patients following endovascular abdominal aortic repair (EVAR). Abdom Radiol (NY). 2017. PMID: 28447108. doi:10.1007/s00261-017-1154-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。